Imperial College London
Alternate

ProfessorDavidDexter

Faculty of Medicine, Department of Brain Sciences

Visiting Professor of Neuropharmacology
 
 
 
//

Contact

 

+44 (0)20 7594 6665d.dexter Website

 
 
//

Location

 

E411Burlington DanesHammersmith Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Martin-Bastida:2017:10.1038/s41598-017-01402-2,
author = {Martin-Bastida, A and Ward, RJ and Newbould, R and Piccini, P and Sharp, D and Kabba, C and Patel, MC and Spino, M and Connelly, J and Tricta, F and Crichton, RR and Dexter, DT},
doi = {10.1038/s41598-017-01402-2},
journal = {Scientific Reports},
title = {Brain iron chelation by deferiprone in a phase 2 randomised double-blinded placebo controlled clinical trial in Parkinson's disease},
url = {http://dx.doi.org/10.1038/s41598-017-01402-2},
volume = {7},
year = {2017}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - Parkinson’s disease (PD) is associated with increased iron levels in the substantia nigra (SNc). This study evaluated whether the iron chelator, deferiprone, is well tolerated, able to chelate iron from various brain regions and improve PD symptomology. In a randomised double-blind, placebo controlled trial, 22 early onset PD patients, were administered deferiprone, 10 or 15 mg/kg BID or placebo, for 6 months. Patients were evaluated for PD severity, cognitive function, depression rating and quality of life. Iron concentrations were assessed in the substantia nigra (SNc), dentate and caudate nucleus, red nucleus, putamen and globus pallidus by T2 MRI at baseline and after 3 and 6 months of treatment. Deferiprone therapy was well tolerated and was associated with a reduced dentate and caudate nucleus iron content compared to placebo. Reductions in iron content of the SNc occurred in only 3 patients, with no changes being detected in the putamen or globus pallidus. Although 30 mg/kg deferiprone treated patients showed a trend for improvement in motor-UPDRS scores and quality of life, this did not reach significance. Cognitive function and mood were not adversely affected by deferiprone therapy. Such data supports more extensive clinical trials into the potential benefits of iron chelation in PD.
AU  - Martin-Bastida,A
AU  - Ward,RJ
AU  - Newbould,R
AU  - Piccini,P
AU  - Sharp,D
AU  - Kabba,C
AU  - Patel,MC
AU  - Spino,M
AU  - Connelly,J
AU  - Tricta,F
AU  - Crichton,RR
AU  - Dexter,DT
DO  - 10.1038/s41598-017-01402-2
PY  - 2017///
SN  - 2045-2322
TI  - Brain iron chelation by deferiprone in a phase 2 randomised double-blinded placebo controlled clinical trial in Parkinson's disease
T2  - Scientific Reports
UR  - http://dx.doi.org/10.1038/s41598-017-01402-2
UR  - http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000400490700009&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202
UR  - http://hdl.handle.net/10044/1/48890
VL  - 7
ER  -
Download